Press releases

ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference

January 3, 2022

GENEVA, Switzerland January 3, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright BioConnect Conference, to be held January 10-13, 2022.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Monday, January 10, 2022.

A webcast can be accessed here and will also be accessible under “Events Calendar” in the investors section of ObsEva’s website, starting Friday, January 14, 2022.

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com

For further information, please contact:

CEO Office Contact:

Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:

Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617)-435-6602

###

ObsEva_HCW-BioConnect-Curtain-Raiser_Jan2022_PCDownload

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue